Why Both Wegovy and Mounjaro Are Available Now
Wegovy and Mounjaro Difference: UK Stock Availability Explained
The wegovy and mounjaro difference in UK availability has been a major concern for patients, but EverydayMeds maintains comprehensive stock of both treatments year-round. Our direct supply partnerships with Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) ensure consistent availability across all dose strengths. Unlike many providers who face frequent shortages, our GPhC-registered pharmacy (#9012878) operates with sufficient inventory buffers to meet demand.
Both treatments require identical cold-chain delivery protocols, which we've perfected through thousands of successful shipments across the UK. The wegovy and mounjaro difference in procurement isn't significant—both manufacturers supply UK pharmacies reliably, but many smaller providers lack the ordering volumes to secure consistent stock. Our established relationships mean patients can access either treatment within 24-48 hours of prescription approval, eliminating the uncertainty that has historically surrounded these medications.
Pricing and Value: Wegovy and Mounjaro Difference Breakdown
The wegovy and mounjaro difference in pricing reflects their distinct development costs and licensing arrangements. Wegovy starts at £79.99 for the 0.25mg starter dose (after applying code FIRST40 at checkout), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenience benefits—the Intro Duo (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks of treatment.
Mounjaro follows a similar escalation pattern but with different dose increments and pricing structures. Both treatments require prescription-only medicine status and clinical assessment through our streamlined online process. Returning customers benefit from code DOSE25 at checkout, while new patients use FIRST40. The wegovy and mounjaro difference in long-term costs depends on your final maintenance dose and individual response, which your prescriber will monitor and adjust accordingly.
Clinical Evidence: Wegovy and Mounjaro Difference in Trial Results
The wegovy and mounjaro difference in clinical evidence stems from their distinct mechanisms and trial designs. Wegovy's STEP programme demonstrated that patients achieved approximately 15% average weight reduction at 68 weeks when used alongside diet and exercise, as published by Wilding et al. in the New England Journal of Medicine, 2021. The STEP trials specifically enrolled participants with obesity or overweight with comorbidities.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual GIP and GLP-1 approach in different patient populations using alternative endpoints and methodologies. Both programmes met their primary efficacy objectives, but direct comparison isn't appropriate due to varying trial designs and participant characteristics. The wegovy and mounjaro difference in evidence quality is less important than finding which mechanism suits your individual clinical profile and treatment goals.
How Wegovy Works: Understanding the Mechanism Behind Results
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. When injected once weekly using the pre-filled FlexTouch pen, semaglutide activates GLP-1 receptors in your brain's appetite control centres, promoting feelings of satiety after smaller meals. This mechanism may reduce food cravings and slow gastric emptying, helping you feel satisfied longer between meals. The treatment must be used alongside a reduced-calorie diet and increased physical activity as part of a comprehensive weight management approach. Clinical studies suggest this single-pathway approach can effectively support weight reduction in adults with BMI ≥30 or BMI ≥27 with weight-related health conditions.
Ordering Process: From Assessment to Next-Day Delivery
Starting either treatment through EverydayMeds takes just three minutes with our online clinical assessment, covering your medical history, current medications, and weight management goals. Our qualified prescribers review every application within three working days (or 24 hours with express service), ensuring treatments are clinically appropriate and safe. Once approved, your prescription-only medicine ships via next-day delivery using temperature-controlled packaging that maintains the 2-8°C storage requirement throughout transit. Our pharmacy team coordinates delivery timing to ensure someone's available to receive your temperature-sensitive medication. You'll receive tracking information and storage guidance, plus access to ongoing clinical support throughout your treatment journey.
Storage and Practical Considerations: Wegovy vs Mounjaro Difference
The wegovy and mounjaro difference in storage requirements significantly impacts daily life and travel flexibility. Wegovy pens remain stable for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, while Mounjaro maintains potency for only 21 days under similar conditions. Both require refrigeration at 2-8°C before first use, but Wegovy's extended room temperature stability makes it superior for business travel, holidays, or situations where refrigeration isn't consistently available. The FlexTouch pen system used by Wegovy features dose confirmation and error prevention mechanisms that some patients find more intuitive than alternative delivery systems. Your treatment starts with mandatory dose escalation over 16 weeks, reaching the 2.4mg maintenance dose that most patients continue long-term.
Supply Chain Reliability: Why Wegovy and Mounjaro Difference Matters Less Now
Historical supply constraints created anxiety around accessing these treatments, but the wegovy and mounjaro difference in availability has largely resolved at established pharmacies like EverydayMeds. We maintain strategic inventory across all dose strengths, working directly with UK distributors to anticipate demand fluctuations. Our GPhC registration (#9012878) enables bulk purchasing agreements that smaller providers cannot access.
Both Novo Nordisk and Eli Lilly have expanded UK manufacturing capacity significantly throughout 2024-2025, stabilising supply chains that previously experienced intermittent shortages. The wegovy and mounjaro difference in procurement difficulty is now minimal for properly established pharmacy operations. Patients can confidently begin either treatment knowing their ongoing supply is secure, eliminating the treatment interruptions that occurred during earlier shortage periods.
Making Your Decision: Expert Prescriber Guidance Available
The wegovy and mounjaro difference becomes clearer when discussed with qualified healthcare professionals who understand your individual circumstances, medical history, and treatment preferences. Our prescriber team evaluates factors including previous weight management attempts, existing health conditions, lifestyle considerations, and personal treatment goals before recommending either option. Both treatments are available through EverydayMeds with identical clinical support standards—your prescriber can help determine which mechanism aligns best with your needs. Remember that weight management represents a long-term commitment regardless of which treatment you choose, with both requiring ongoing lifestyle modifications for optimal results. Start your clinical assessment today using code FIRST40 at checkout, knowing that expert guidance and reliable UK supply make either choice a viable path forward: https://everydaymeds.co.uk/collections/wegovy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
